Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pharmacokinetics and tolerance of zidovudine in preterm infants.

Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, Gay H, Ciupak G, Smith B, Connor JD; Pediatric AIDS Clinical Trials Group 331 Investigators..

J Pediatr. 2003 Jan;142(1):47-52.

PMID:
12520254
2.

Pharmacokinetics of zidovudine in infants: a population analysis across studies.

Mirochnick M, Capparelli E, Connor J.

Clin Pharmacol Ther. 1999 Jul;66(1):16-24.

PMID:
10430105
3.

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R Jr, Crain MJ, Elkins MM, et al.

J Pediatr. 1993 Jan;122(1):137-44.

PMID:
8419601
4.

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE.

J Clin Pharmacol. 2001 Jul;41(7):732-41.

PMID:
11452705
5.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D.

Antiviral Res. 2000 Jan;45(1):47-58.

PMID:
10774589
6.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
7.

Alternative dosage of zidovudine in infants exposed to maternal human immunodeficiency virus infection.

Frasca K, Fisher RG, McGuire E.

Pediatr Infect Dis J. 2009 Dec;28(12):1131-2. doi: 10.1097/INF.0b013e3181af59eb.

PMID:
19841608
8.

Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.

Briand N, Le Coeur S, Traisathit P, Karnchanamayul V, Hansudewechakul R, Ngampiyasakul C, Bhakeecheep S, Ithisukanan J, Hongsiriwon S, McIntosh K, Lallemant M.

Pediatr Infect Dis J. 2006 Apr;25(4):325-32.

PMID:
16567984
9.

A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.

Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, Boyle E, Chitsike I, Chipato T, Gottesman M, Silverman M.

Clin Infect Dis. 2007 Jan 1;44(1):111-9. Epub 2006 Nov 22.

PMID:
17143826
10.

Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants.

Prasitwattanaseree S, Lallemant M, Costagliola D, Jourdain G, Mary JY.

Antivir Ther. 2004 Apr;9(2):179-85.

PMID:
15134179
11.

Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.

Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A.

HIV Med. 2007 Oct;8(7):451-6.

12.

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.

Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, Stevens L, Peter T, Essex M, Connor JD, Mirochnick M.

J Infect Dis. 2005 Sep 1;192(5):720-7. Epub 2005 Jul 27.

PMID:
16088821
13.

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team..

Pediatr Infect Dis J. 2005 Sep;24(9):793-800.

PMID:
16148846
14.
15.

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Verweij C, van Rossum AM, Verweel G, Hartwig NG, de Groot R, Burger DM.

J Antimicrob Chemother. 2004 Dec;54(6):1152-4. Epub 2004 Nov 10.

PMID:
15537694
16.

Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L.

AIDS. 2006 Jan 9;20(2):217-22.

PMID:
16511414
17.

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL; South African Intrapartum Nevirapine Trial (SAINT) Investigators..

J Infect Dis. 2003 Mar 1;187(5):725-35. Epub 2003 Feb 24.

PMID:
12599045
18.

Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission.

Bhoopat L, Khunamornpong S, Lerdsrimongkol P, Sirivatanapa P, Sethavanich S, Limtrakul A, Gomutbuthra V, Kajanavanich S, Thorner PS, Bhoopat T.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):545-50.

PMID:
16284530
19.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

PMID:
19832114
20.

Implications of the kinetics of zidovudine in the pregnant baboon following oral administration.

Garland M, Szeto HH, Daniel SS, Tropper PJ, Myers MM, Stark RI.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):433-40.

PMID:
9859956

Supplemental Content

Support Center